LEVERKUSEN, Germany, March 18 /PRNewswire-FirstCall/ -- Bayer (NYSE: BAY)
said it is pleased that the jury in the Corpus Christi, Texas, U.S.A. Baycol
trial reached a verdict in its favor. The verdict validates Bayer's assertion
that the company acted responsibly in the development, marketing and voluntary
withdrawal of Baycol.
Bayer will now turn its attention to the other pending Baycol cases to
analyze the specific circumstances of each case and the nature of the claims.
It is Bayer's intention to pursue its policy of seeking to fairly compensate
anyone who experienced serious side effects from Baycol, regardless of whether
we have valid legal defenses to such claims. At the same time, where an
examination of the facts indicates that Baycol played no role in the patient's
medical situation, or where a settlement is not achieved, Bayer will continue
to defend itself vigorously as it did in the Corpus Christi case.
Bayer News Conference: 12:30 p.m. CST USA/7:30 p.m. CET
Domestic dial-in: 1-800-478-6251
International dial-in: 913-981-5558
Forward-looking statements
This news release contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group management. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in our public reports filed with the Frankfurt
Stock Exchange and with the U.S. Securities and Exchange Commission (including
our Form 20-F). The company assumes no liability whatsoever to update these
forward-looking statements or to conform them to future events or
developments.
SOURCE Bayer
 back to top
Related links:
http://www.bayerus.com
Company News On-Call:
http://www.prnewswire.com/comp/092575.html
CONTACT:
Annette Josten, +49 214 30 62812,
annette.josten.aj@bayer-ag.de, or Meredith Fischer,
+1-203-812-6485, meredith.fischer.b@bayer.com, or Mark Ryan,
+1-412-777-5666, mark-a.ryan.b@bayer.com, all of Bayer
|
